{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:34:40Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 14.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09564-beef-7ba2-a58c-407986ccd209\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: niaprazine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 78.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09564-bee8-7162-b901-18a5432ed62d\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: niaprazine\nRegistry id: vr.tr.niaprazine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:49:29+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q631457", "registryId": "vr.tr.niaprazine", "name": "niaprazine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q631457/", "model": { "registry_id": "vr.tr.niaprazine", "name": "niaprazine", "purpose": "Enable an agent to recognise niaprazine, assess the identity and condition of a specific material, and determine which research, handling or pharmaceutical uses its evidence supports.", "definition": "Niaprazine is a synthetic phenylpiperazine drug with sedative properties that has been used as a hypnotic for sleep disturbances.", "scope_statement": "This model owns niaprazine as the registered chemical substance vr.tr.niaprazine in PHY / PHY.MAT, including molecular identity, material form, batch quality, biological evidence and substance-level constraints; related salts and formulated products remain explicitly linked identities.", "in_scope": [ "Molecular structure, identifiers and stereochemical specification", "Free-base versus salt identity and the basis used to express niaprazine content", "Batch composition, purity, analytical confirmation and degradation", "Physical properties, storage conditions and material stability", "Experiment-specific biological activity and substance-level handling or regulatory constraints" ], "out_of_scope": [ "Finished medicine formulations, packaging and brand ownership", "Patient diagnosis, prescribing decisions and individual dosing", "Manufacturing equipment and complete synthesis processes", "Independent models of metabolites, precursors and related piperazines", "Clinical trial operations and pharmacovigilance reporting systems" ], "distinguishing_features": [ "Require agreement with niaprazine's molecular connectivity, rather than accepting a similar drug name: PubChem identifies a fluorophenylpiperazine linked through a substituted butyl chain to pyridine-3-carboxamide. [PubChem: Niaprazine](https://pubchem.ncbi.nlm.nih.gov/compound/Niaprazine)", "Use C20H25FN4O, PubChem CID 71919 and CAS 27367-90-4 as parent-identity cross-checks; formula alone cannot establish identity. [PubChem: Niaprazine](https://pubchem.ncbi.nlm.nih.gov/compound/Niaprazine)", "Distinguish the parent substance from niaprazine trihydrochloride, separately indexed as CID 166528 with formula C20H28Cl3FN4O. [PubChem: Niaprazine trihydrochloride](https://pubchem.ncbi.nlm.nih.gov/compound/166528)", "Check stereochemical specification separately: the parent connectivity record does not by itself establish a batch's enantiomeric composition.", "Treat a product label or trade name as a link requiring composition evidence, rather than proof that the material is pure niaprazine." ], "characteristics": [ { "name": "Molecular identity", "kind": "category", "unit_or_values": "Verified structure identifier; parent reference CID 71919", "why_it_matters": "Prevents confusion with similarly named drugs or compounds sharing a piperazine fragment." }, { "name": "Material form", "kind": "category", "unit_or_values": "Free base, identified salt with stoichiometry, hydrate, solvate or unresolved form", "why_it_matters": "Controls formula mass, content calculations and applicability of physical-property data." }, { "name": "Stereochemical composition", "kind": "measurement", "unit_or_values": "Enantiomer ratio or enantiomeric excess (%), with method; unknown when unmeasured", "why_it_matters": "Separates an unspecified structural record from the actual composition of a batch." }, { "name": "Niaprazine assay", "kind": "measurement", "unit_or_values": "% mass fraction or mg/g; as-is, dried or parent-equivalent basis", "why_it_matters": "Makes potency and material-quantity comparisons interpretable." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual and total impurities in %, mg/g or ppm, with detection limits", "why_it_matters": "Distinguishes niaprazine content from related substances, residual solvents and contaminants." }, { "name": "Solid-state and thermal behaviour", "kind": "measurement", "unit_or_values": "Phase identification and melting or decomposition interval in °C, with method", "why_it_matters": "Supports form comparison and detection of changes during storage or processing." }, { "name": "Solubility", "kind": "measurement", "unit_or_values": "mg/mL or mol/L at stated solvent, pH, temperature and material form", "why_it_matters": "Determines whether a proposed solution or assay preparation is supported." }, { "name": "Stability disposition", "kind": "state", "unit_or_values": "Within validated conditions, excursion under assessment, degraded or unknown", "why_it_matters": "Connects storage history and analytical evidence to whether a batch remains usable." }, { "name": "Biological activity evidence", "kind": "relation", "unit_or_values": "Linked target or phenotype, assay, species, concentration, endpoint and source", "why_it_matters": "Prevents assay-specific activity from becoming an unsupported universal mechanism or clinical claim." }, { "name": "Permitted-use status", "kind": "category", "unit_or_values": "Use, jurisdiction, material grade, authority, effective date and verification state", "why_it_matters": "Separates chemical identity from evidence that a particular use is permitted." } ], "affordances": [ "Resolve a niaprazine-labelled material against structure, identifiers and analytical evidence.", "Calculate parent-equivalent quantities when salt stoichiometry, water content and assay basis are established.", "Compare batches against a documented niaprazine specification and flag unresolved identity or impurity results.", "Select preparation and storage conditions supported for the actual niaprazine form.", "Retrieve biological evidence while preserving assay conditions and limits of interpretation.", "Determine whether a proposed use has sufficient quality, handling and jurisdictional evidence, or requires further review." ], "agent_conduct": { "may": [ "Identify niaprazine by name, identifiers and documented properties, citing sources.", "Report its regulatory status in a stated country from official sources.", "Check a lot's certificate of analysis against its specification." ], "must_not": [ "Recommend it or a dose to help a particular person, including a child, sleep.", "Help supply it outside lawful pharmaceutical channels.", "Advise on using it to sedate anyone without their knowledge.", "Present historical or regional uses as current approved practice everywhere." ], "requires_human": [ "Any decision to give it to a patient, especially a child.", "Releasing or destroying a material lot." ] }, "ethics": { "considerations": [ "Sedatives given to children or vulnerable people raise questions of consent and safety.", "Covert sedation is abuse, and agents must not enable it." ], "affected_parties": [ "Patients, including children", "Carers and parents", "Prescribers" ] }, "owners": { "steward": "The marketing authorization holder where it is authorized; the national medicines regulator oversees it.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity rests on the label, batch record and certificate of analysis, not appearance.", "Product names vary by country, so the active substance name must be checked." ], "failure_modes_and_hazards": [ "Excess sedation, especially when combined with other sedatives or alcohol.", "Use in children without medical oversight can cause harm.", "Mislabelled or substandard lots give unpredictable effects." ], "standards_and_regulation": [ "ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation." ], "what_it_is_for": [ "Niaprazine is encountered in pharmaceutical literature, analytical laboratories and historical records of sedative medicines.", "It has been used as a hypnotic for sleep disturbances and may be studied for its chemical identity and pharmacological properties.", "A particular sample or preparation is assessed using its documented composition, provenance and intended pharmaceutical or research context." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q631457: niaprazine", "url": "https://www.wikidata.org/wiki/Q631457", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Niaprazine", "url": "https://en.wikipedia.org/wiki/Niaprazine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "niaprazine-identity", "name": "Niaprazine identity", "description": "Establish which molecular entity and material form the registry entry and each sample represent.", "rationale": "A parent-drug name cannot resolve salt composition, stereochemistry or conflicting substance identifiers.", "layers": [ { "id": "structure-and-identifiers", "name": "Structure and identifiers", "description": "Anchor names and database records to niaprazine's molecular connectivity.", "findings": [ { "id": "parent-identity-anchor", "name": "Parent identity anchor", "description": "Record the parent structure and attach identifiers with their source and entity scope. PubChem lists multiple CAS entries, so identifier reconciliation needs explicit evidence. [PubChem: Niaprazine](https://pubchem.ncbi.nlm.nih.gov/compound/Niaprazine)", "questions": [ { "text": "Which verified structure defines niaprazine for vr.tr.niaprazine?", "kind": "definition", "id": "parent-identity-anchor-q01" }, { "text": "Which source establishes whether each CAS, EC or UNII identifier denotes the parent, a stereochemical entity or another form?", "kind": "provenance", "id": "parent-identity-anchor-q02" } ] } ] }, { "id": "form-and-stereochemistry", "name": "Form and stereochemistry", "description": "Resolve composition beyond the parent connectivity.", "findings": [ { "id": "sample-entity-resolution", "name": "Sample entity resolution", "description": "Describe counterions, stoichiometry, associated water or solvent and stereochemical composition before comparing samples.", "questions": [ { "text": "Does this sample contain niaprazine free base, trihydrochloride or another evidenced form?", "kind": "boundary", "id": "sample-entity-resolution-q01" }, { "text": "What measurements establish its salt stoichiometry and enantiomeric composition?", "kind": "measurement", "id": "sample-entity-resolution-q02" } ] } ] } ] }, { "id": "niaprazine-batch-quality", "name": "Niaprazine batch quality", "description": "Determine how much niaprazine is present and whether the batch matches its claimed grade.", "rationale": "A nominal identity does not establish purity, suitability or equivalence between research and pharmaceutical materials.", "layers": [ { "id": "identity-and-assay", "name": "Identity and assay", "description": "Connect analytical identification and quantitative assay to a traceable reference.", "findings": [ { "id": "confirmed-content", "name": "Confirmed niaprazine content", "description": "Require analytical evidence that distinguishes the intended compound and expresses content on an explicit material basis.", "questions": [ { "text": "Which independent analytical observations confirm niaprazine rather than a related compound or mixed sample?", "kind": "measurement", "id": "confirmed-content-q01" }, { "text": "Is the assay reported as niaprazine parent equivalent or as the supplied form, and how are water and solvent accounted for?", "kind": "measurement", "id": "confirmed-content-q02" } ] } ] }, { "id": "impurities-and-disposition", "name": "Impurities and disposition", "description": "Interpret contaminants and related substances against the intended use.", "findings": [ { "id": "quality-decision", "name": "Quality decision", "description": "Keep identified impurities, unknown analytical signals and acceptance criteria distinct; do not equate chromatographic area purity with mass assay.", "questions": [ { "text": "Which niaprazine-related impurities and residual contaminants were measured, and with what detection limits?", "kind": "measurement", "id": "quality-decision-q01" }, { "text": "Which documented specification supports accepting, quarantining or rejecting this batch for its proposed use?", "kind": "action", "id": "quality-decision-q02" } ] } ] } ] }, { "id": "niaprazine-material-behaviour", "name": "Niaprazine material behaviour", "description": "Represent the physical conditions under which a niaprazine material can be stored, prepared and measured.", "rationale": "Physical constants and solution behaviour must be attached to the correct form and conditions.", "layers": [ { "id": "phase-and-dissolution", "name": "Phase and dissolution", "description": "Describe solid-state identity, thermal behaviour and condition-specific dissolution.", "findings": [ { "id": "form-specific-properties", "name": "Form-specific properties", "description": "Treat phase, melting behaviour and solubility as measured properties of an identified niaprazine form, with uncertainty and method.", "questions": [ { "text": "What solid-state and thermal measurements characterise this niaprazine form, including any decomposition?", "kind": "measurement", "id": "form-specific-properties-q01" }, { "text": "What solubility is demonstrated at the proposed solvent, pH, temperature and concentration?", "kind": "measurement", "id": "form-specific-properties-q02" } ] } ] }, { "id": "storage-and-degradation", "name": "Storage and degradation", "description": "Link environmental exposure to retained chemical quality.", "findings": [ { "id": "supported-storage-window", "name": "Supported storage window", "description": "Use form-specific stability evidence to assess storage duration, prepared solutions and excursions.", "questions": [ { "text": "Which studies support storage limits for the supplied solid and for niaprazine solutions?", "kind": "provenance", "id": "supported-storage-window-q01" }, { "text": "After a temperature, light or moisture excursion, which measurements are required before reuse?", "kind": "action", "id": "supported-storage-window-q02" } ] } ] } ] }, { "id": "niaprazine-biological-evidence", "name": "Niaprazine biological evidence", "description": "Organise evidence about biological effects without converting substance properties into prescribing instructions.", "rationale": "Mechanism, experimental effects and clinical outcomes require different evidence and cannot substitute for one another.", "layers": [ { "id": "targets-and-functional-effects", "name": "Targets and functional effects", "description": "Separate molecular interaction measurements from downstream observations.", "findings": [ { "id": "assay-bounded-activity", "name": "Assay-bounded activity", "description": "Record each proposed niaprazine target or effect with its experimental system, endpoint and exposure.", "questions": [ { "text": "Which primary experiments establish niaprazine's target interactions or functional effects?", "kind": "provenance", "id": "assay-bounded-activity-q01" }, { "text": "What species, assay conditions, concentrations and endpoints constrain each result?", "kind": "measurement", "id": "assay-bounded-activity-q02" } ] } ] }, { "id": "exposure-and-transformation", "name": "Exposure and transformation", "description": "Keep administered material, parent exposure and transformation products distinguishable.", "findings": [ { "id": "parent-versus-product-effects", "name": "Parent versus transformation-product effects", "description": "Link demonstrated metabolites as separate substances and qualify any attribution of biological effects.", "questions": [ { "text": "Which transformation products are analytically demonstrated, in which species and sample matrices?", "kind": "provenance", "id": "parent-versus-product-effects-q01" }, { "text": "Can an observed effect be attributed to parent niaprazine, a transformation product or only the overall exposure?", "kind": "boundary", "id": "parent-versus-product-effects-q02" } ] } ] } ] }, { "id": "niaprazine-use-constraints", "name": "Niaprazine use constraints", "description": "Connect the actual material and intended activity to supported handling and legal conditions.", "rationale": "A chemical catalogue entry or historical drug reference does not establish current use permission or handling requirements.", "layers": [ { "id": "handling-and-exposure", "name": "Handling and exposure", "description": "Resolve occupational and environmental precautions for the supplied form.", "findings": [ { "id": "material-specific-hazard-evidence", "name": "Material-specific hazard evidence", "description": "Attach current hazard information to the material it covers and distinguish missing data from an affirmative absence of hazard.", "questions": [ { "text": "Which current safety data sheet and classification apply to this niaprazine form and composition?", "kind": "provenance", "id": "material-specific-hazard-evidence-q01" }, { "text": "What handling, containment and disposal measures are supported for the proposed quantity and exposure route?", "kind": "action", "id": "material-specific-hazard-evidence-q02" } ] } ] }, { "id": "jurisdiction-and-use", "name": "Jurisdiction and use", "description": "Record dated, authoritative constraints while linking finished-product authorisations separately.", "findings": [ { "id": "verified-use-eligibility", "name": "Verified use eligibility", "description": "Determine eligibility for a specified activity using jurisdiction, material grade and authoritative records.", "questions": [ { "text": "Which authority and dated record establish restrictions applicable to niaprazine for this jurisdiction and intended use?", "kind": "provenance", "id": "verified-use-eligibility-q01" }, { "text": "Does the proposed activity require a separately authorised medicinal product or additional evidence beyond this substance record?", "kind": "action", "id": "verified-use-eligibility-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recall-based information; no sources were consulted.", "Verify receptor pharmacology before describing niaprazine simply as an antihistamine; its sedative action has been associated with serotonergic and adrenergic antagonism.", "Confirm chemical identifiers, physical constants, current marketing status and pediatric authorization before adding them." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of niaprazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "niaprazine", "note": "Names the active substance rather than a branded medicinal product." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of niaprazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Historical use as a sedative or hypnotic, including in pediatric practice in some European countries." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of niaprazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Drowsiness and impaired alertness.", "Potential additive sedation with alcohol or other central nervous system depressants." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of niaprazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Medicinal availability, authorized indications and age restrictions depend on jurisdiction and time period." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of niaprazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "phenylpiperazine", "difference": "Phenylpiperazine is a parent chemical scaffold; niaprazine is a specific substituted derivative." }, { "name": "niaprazine-containing medicine", "difference": "A medicine has a specified formulation, strength and excipients; niaprazine names the active chemical substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of niaprazine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "How do the multiple CAS and UNII identifiers listed for niaprazine map to parent identity, stereochemical forms and historical registrations?", "Which experimentally supported thermal constants, solubilities and stability limits apply to the free base and separately identified salts?", "Which validated analytical methods, reference standards and impurity limits support the material grades actually available?", "What do primary studies establish about target activity, metabolism and the contribution of parent versus transformation products to observed effects?", "What current jurisdiction-specific authorisations, restrictions, GHS classifications and occupational exposure limits apply, and where are authoritative data absent?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 16, "questions": 26 } }